Lifetime methamphetamine dependence is associated with cerebral microgliosis in HIV-1-infected adults

Journal of NeuroVirology

Volumn 22, Issue 5, 2016, Pages 650-660

  Soontornniyomkij, Virawudh ^a   Umlauf, Anya ^a   Soontornniyomkij, Benchawanna ^a   Batki, Isabella B ^a   Moore, David J ^a   Masliah, Eliezer ^a,b   Achim, Cristian L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arteriolosclerosis; Astrogliosis; Methamphetamine; Microgliosis; Small vessel disease; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; GLIAL FIBRILLARY ACIDIC PROTEIN; IONIZED CALCIUM BINDING ADAPTER MOLECULE 1; MICROTUBULE ASSOCIATED PROTEIN 2; PEPTIDES AND PROTEINS; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; AIF1 PROTEIN, HUMAN; DNA BINDING PROTEIN; MAP2 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; SYP PROTEIN, HUMAN;

ADULT; ALCOHOLISM; ARTERIOLOSCLEROSIS; ARTICLE; ASTROCYTOSIS; CANNABIS ADDICTION; CAPSULA INTERNA; CELL LOSS; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; ENCEPHALITIS; FEMALE; FOREBRAIN; FRONTAL CORTEX; GLIOSIS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; MALE; METHAMPHETAMINE DEPENDENCE; OPIATE ADDICTION; OPPORTUNISTIC INFECTION; PARIETAL CORTEX; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PUTAMEN; TEMPORAL CORTEX; WHITE MATTER; WHITE MATTER LESION; AGED; AMPHETAMINE DEPENDENCE; AUTOPSY; COMPLICATION; FRONTAL LOBE; GENE EXPRESSION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MIDDLE AGED; PARIETAL LOBE; PATHOLOGY; PATHOPHYSIOLOGY; TEMPORAL LOBE;

ADULT; AGED; ALCOHOLISM; AMPHETAMINE-RELATED DISORDERS; AMYLOID BETA-PEPTIDES; AUTOPSY; DNA-BINDING PROTEINS; FEMALE; FRONTAL LOBE; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; HIV INFECTIONS; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; OPIOID-RELATED DISORDERS; PARIETAL LOBE; PROSENCEPHALON; PUTAMEN; SYNAPTOPHYSIN; TEMPORAL LOBE; WHITE MATTER;

EID: 84964331074     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-016-0441-8     Document Type: Article

References (44)

1. Bae SC, Lyoo IK, Sung YH, Yoo J, Chung A, Yoon SJ, Kim DJ, Hwang J, Kim SJ, Renshaw PF (2006) Increased white matter hyperintensities in male methamphetamine abusers. Drug Alcohol Depend 81:83–88
2. Beitner-Johnson D, Guitart X, Nestler EJ (1993) Glial fibrillary acidic protein and the mesolimbic dopamine system: regulation by chronic morphine and Lewis-Fischer strain differences in the rat ventral tegmental area. J Neurochem 61:1766–1773
3. Bortell N, Morsey B, Basova L, Fox HS, Marcondes MC (2015) Phenotypic changes in the brain of SIV-infected macaques exposed to methamphetamine parallel macrophage activation patterns induced by the common gamma-chain cytokine system. Front Microbiol 6:900
4. Bowyer JF, Robinson B, Ali S, Schmued LC (2008) Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure. Synapse 62:193–204
5. Bryant AK, Ellis RJ, Umlauf A, Gouaux B, Soontornniyomkij V, Letendre SL, Achim CL, Masliah E, Grant I, Moore DJ (2015) Antiretroviral therapy reduces neurodegeneration in HIV infection. AIDS 29:323–330
6. Budka H, Wiley CA, Kleihues P, Artigas J, Asbury AK, Cho ES, Cornblath DR, Dal Canto MC, DeGirolami U, Dickson D (1991) HIV-associated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology. Brain Pathol 1:143–152
7. Cadet JL, Krasnova IN (2007) Interactions of HIV and methamphetamine: cellular and molecular mechanisms of toxicity potentiation. Neurotox Res 12:181–204
8. Carey CL, Woods SP, Rippeth JD, Gonzalez R, Heaton RK, Grant I (2006) Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav 10:185–190
9. Chana G, Everall IP, Crews L, Langford D, Adame A, Grant I, Cherner M, Lazzaretto D, Heaton R, Ellis R, Masliah E (2006) Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology 67:1486–1489
10. Chang L, Ernst T, Speck O, Grob CS (2005) Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry 162:361–369
11. Everall I, Salaria S, Roberts E, Corbeil J, Sasik R, Fox H, Grant I, Masliah E (2005) Methamphetamine stimulates interferon inducible genes in HIV infected brain. J Neuroimmunol 170:158–171
12. Fowler JS, Volkow ND, Logan J, Alexoff D, Telang F, Wang GJ, Wong C, Ma Y, Kriplani A, Pradhan K, Schlyer D, Jayne M, Hubbard B, Carter P, Warner D, King P, Shea C, Xu Y, Muench L, Apelskog K (2008) Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine. Neuroimage 43:756–763
13. Frank MG, Adhikary S, Sobesky JL, Weber MD, Watkins LR, Maier SF (2016) The danger-associated molecular pattern HMGB1 mediates the neuroinflammatory effects of methamphetamine. Brain Behav Immun 51:99–108
14. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J (1996) Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry 153:1195–1201
15. Hoefer MM, Sanchez AB, Maung R, de Rozieres CM, Catalan IC, Dowling CC, Thaney VE, Piña-Crespo J, Zhang D, Roberts AJ, Kaul M (2015) Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system. Exp Neurol 263:221–234
16. Huitron-Resendiz S, Henriksen SJ, Barr MC, Testa MP, Crawford E, Parsons LH, Sanchez-Alavez M, Phillips TR (2010) Methamphetamine and lentivirus interactions: reciprocal enhancement of central nervous system disease. J Neurovirol 16:268–278
17. Kalasinsky KS, Bosy TZ, Schmunk GA, Reiber G, Anthony RM, Furukawa Y, Guttman M, Kish SJ (2001) Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. Forensic Sci Int 116:163–169
18. Kitamura O, Takeichi T, Wang EL, Tokunaga I, Ishigami A, Kubo S (2010) Microglial and astrocytic changes in the striatum of methamphetamine abusers. Leg Med (Tokyo) 12:57–62
19. Kuhn DM, Angoa-Pérez M, Thomas DM (2011) Nucleus accumbens invulnerability to methamphetamine neurotoxicity. ILAR J 52:352–365
20. Langford D, Adame A, Grigorian A, Grant I, McCutchan JA, Ellis RJ, Marcotte TD, Masliah E (2003) Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr 34:467–474
21. Letendre S, Paulino AD, Rockenstein E, Adame A, Crews L, Cherner M, Heaton R, Ellis R, Everall IP, Grant I, Masliah E (2007) Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 196:361–370
22. Letendre SL, Ellis RJ, Ances BM, McCutchan JA (2010) Neurologic complications of HIV disease and their treatment. Top HIV Med 18:45–55
23. Loftis JM, Janowsky A (2014) Neuroimmune basis of methamphetamine toxicity. Int Rev Neurobiol 118:165–197
24. McConnell SE, O’Banion MK, Cory-Slechta DA, Olschowka JA, Opanashuk LA (2015) Characterization of binge-dosed methamphetamine-induced neurotoxicity and neuroinflammation. Neurotoxicology 50:131–141
25. Mediouni S, Garibaldi Marcondes MC, Miller C, McLaughlin JP, Valente ST (2015) The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders. Front Microbiol 6:1164
26. Nordahl TE, Salo R, Natsuaki Y, Galloway GP, Waters C, Moore CD, Kile S, Buonocore MH (2005) Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 62:444–452
27. Ovbiagele B, Saver JL (2006) Cerebral white matter hyperintensities on MRI: current concepts and therapeutic implications. Cerebrovasc Dis 22:83–90
28. Pantoni L (2010) Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9:689–701
29. Persidsky Y, Ho W, Ramirez SH, Potula R, Abood ME, Unterwald E, Tuma R (2011) HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. Brain Behav Immun 25(Suppl 1):S61–S70
30. Prinz M, Priller J (2014) Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci 15:300–312
31. Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R, Wolfson T, Grant I (2004) Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 10:1–14
32. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA (1988) The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45:1069–1077
33. Salo R, Buonocore MH, Leamon M, Natsuaki Y, Waters C, Moore CD, Galloway GP, Nordahl TE (2011) Extended findings of brain metabolite normalization in MA-dependent subjects across sustained abstinence: a proton MRS study. Drug Alcohol Depend 113:133–138
34. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, Nakamura K, Iwata Y, Tsuchiya KJ, Suda S, Suzuki K, Kawai M, Takebayashi K, Yamamoto S, Matsuzaki H, Ueki T, Mori N, Gold MS, Cadet JL (2008) Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 28:5756–5761
35. Soontornniyomkij V, Moore DJ, Gouaux B, Soontornniyomkij B, Tatro ET, Umlauf A, Masliah E, Levine AJ, Singer EJ, Vinters HV, Gelman BB, Morgello S, Cherner M, Grant I, Achim CL (2012a) Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. AIDS 26:2327–2335
36. Soontornniyomkij V, Risbrough VB, Young JW, Wallace CK, Soontornniyomkij B, Jeste DV, Achim CL (2010) Short-term recognition memory impairment is associated with decreased expression of FK506 binding protein 51 in the aged mouse brain. Age (Dordr) 32:309–322
37. Soontornniyomkij V, Soontornniyomkij B, Moore DJ, Gouaux B, Masliah E, Tung S, Vinters HV, Grant I, Achim CL (2012b) Antioxidant sestrin-2 redistribution to neuronal soma in human immunodeficiency virus-associated neurocognitive disorders. J Neuroimmune Pharmacol 7:579–590
38. Soontornniyomkij V, Umlauf A, Chung SA, Cochran ML, Soontornniyomkij B, Gouaux B, Toperoff W, Moore DJ, Masliah E, Ellis RJ, Grant I, Achim CL (2014) HIV protease inhibitor exposure predicts cerebral small vessel disease. AIDS 28:1297–1306
39. Taylor MJ, Schweinsburg BC, Alhassoon OM, Gongvatana A, Brown GG, Young-Casey C, Letendre SL, Grant I (2007) Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy. J Neurovirol 13:150–159
40. Tong J, Fitzmaurice P, Furukawa Y, Schmunk GA, Wickham DJ, Ang LC, Sherwin A, McCluskey T, Boileau I, Kish SJ (2014) Is brain gliosis a characteristic of chronic methamphetamine use in the human? Neurobiol Dis 67:107–118
41. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J (2001) Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21:9414–9418
42. Volkow ND, Fowler JS, Wang GJ, Shumay E, Telang F, Thanos PK, Alexoff D (2010) Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PLoS One 5:e15269
43. Wang GJ, Volkow ND, Chang L, Miller E, Sedler M, Hitzemann R, Zhu W, Logan J, Ma Y, Fowler JS (2004) Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry 161:242–248
44. Yang S, Belcher AM, Chefer S, Vaupel DB, Schindler CW, Stein EA, Yang Y (2015) Withdrawal from long-term methamphetamine self-administration ‘normalizes’ neurometabolites in rhesus monkeys: a (1) H MR spectroscopy study. Addict Biol 20:69–79